T cell senescence and CAR-T cell exhaustion in hematological malignancies

被引：189
作者：
Kasakovski, Dimitri [1 ,2 ]
Xu, Ling [1 ,3 ]
Li, Yangqiu [1 ,3 ]
机构：
[1] Jinan Univ, Key Lab Regenerat Med, Minist Educ, Inst Hematol,Sch Med, Guangzhou 510632, Guangdong, Peoples R China
[2] Ruhr Univ Bochum, Dept Anat & Mol Embryol, Inst Anat, D-44801 Bochum, Germany
[3] Jinan Univ, Dept Hematol, Affiliated Hosp 1, Sch Med, 601 West Huangpu Ave, Guangzhou 510632, Guangdong, Peoples R China
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2018年 / 11卷
基金：
中国国家自然科学基金;
关键词：
T cells; Senescence; Hematological malignancy; T cell activation; CAR-T cells; UMBILICAL-CORD BLOOD; IMMUNE MODULATION; REPLICATIVE SENESCENCE; REGENERATIVE THERAPY; 4-1BB COSTIMULATION; ENVIRONMENTAL CUES; TUMOR-IMMUNITY; CANCER; TRANSPLANTATION; INDUCTION;
D O I：
10.1186/s13045-018-0629-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
T cell senescence has been recognized to play an immunosuppressive role in the aging population and cancer patients. Strategies dedicated to preventing or reversing replicative and premature T cell senescence are required to increase the lifespan of human beings and to reduce the morbidity from cancer. In addition, overcoming the T cell terminal differentiation or senescence from lymphoma and leukemia patients is a promising approach to enhance the effectiveness of adoptive cellular immunotherapy (ACT). Chimeric antigen receptor T (CAR-T) cell and T cell receptor-engineered T (TCR-T) cell therapy highly rely on functionally active T cells. However, the mechanisms which drive T cell senescence remain unclear and controversial. In this review, we describe recent progress for restoration of T cell homeostasis from age-related senescence as well as recovery of T cell activation in hematological malignancies.
引用
收藏
页数：9
相关论文
共 50 条
  • [41] Oncolytic virus and CAR-T cell therapy in solid tumors
    Ponterio, Eleonora
    Haas, Tobias Longin
    De Maria, Ruggero
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [42] A Tumor-Agnostic TCR-Mimic CAR-T cell Specific for NDC80 Targets Multiple Hematological Malignancies
    Klatt, Martin G.
    Dao, Tao
    Yang, Zhiyuan
    Liu, Jianying
    Mun, Sung Soo
    Dacek, Megan M.
    Luo, Hanzhi
    Gardner, Thomas J.
    Bourne, Christopher
    Peraro, Leila
    Aretz, Zita E. H.
    Korontsvit, Tanya
    Kharas, Michael G.
    Liu, Cheng
    Scheinberg, David A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S447 - S448
  • [43] Current challenges and emerging opportunities of CAR-T cell therapies
    Abreu, Teresa R.
    Fonseca, Nuno A.
    Goncalves, Nelio
    Moreira, Joao Nuno
    JOURNAL OF CONTROLLED RELEASE, 2020, 319 : 246 - 261
  • [44] In-depth analysis of the safety of CAR-T cell therapy for solid tumors
    Dong, Jiayi
    Wu, Jiexiong
    Jin, Ye
    Zheng, Zhu
    Su, Ting
    Shao, Lijuan
    Bei, Jiaxin
    Chen, Size
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [45] Choosing T-cell sources determines CAR-T cell activity in neuroblastoma
    Garcia-Garcia, Lorena
    Sanchez, Elena G.
    Ivanova, Mariya
    Pastora, Keren
    Alcantara-Sanchez, Cristina
    Garcia-Martinez, Jorge
    Martin-Antonio, Beatriz
    Ramirez, Manuel
    Gonzalez-Murillo, Africa
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [46] Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies
    Beider, Katia
    Itzhaki, Orit
    Schachter, Jacob
    Grushchenko-Polaq, Ania Hava
    Voevoda-Dimenshtein, Valeria
    Rosenberg, Evgenia
    Ostrovsky, Olga
    Devillers, Olivia
    Frommer, Ronnie Shapira
    Zeltzer, Li-At
    Toren, Amos
    Jacoby, Elad
    Shimoni, Avichai
    Avigdor, Abraham
    Nagler, Arnon
    Besser, Michal J.
    CELLS, 2022, 11 (07)
  • [47] Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies
    Arunachalam, Arun K.
    Gregoire, Celine
    de Oliveira, Beatriz Coutinho
    Melenhorst, Jan Joseph
    BLOOD REVIEWS, 2024, 68
  • [48] The Role of Cancer-Specific Target Antigens in CAR T Cell Therapy in Hematological Malignancies
    Tabish H. Khan
    Naoshad Muhammad
    Mohammad Tarique
    Darksha Usmani
    Huma Naz
    Aditya Sarode
    Current Tissue Microenvironment Reports, 2024, 5 (2): : 61 - 67
  • [49] In Vitro Cytotoxic Rechallenge to Model Active CAR-T and NK Cell Cytotoxic Activity, Exhaustion, and Persistence
    Moreno, Eider
    Forero-Forero, Jose
    Garcia-Robledo, Juan E.
    Booth, Natalie
    Franco-Fuquen, Pedro
    Castro, Januario
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S443 - S444
  • [50] T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
    Crespo, Joel
    Sun, Haoyu
    Welling, Theodore H.
    Tian, Zhigang
    Zou, Weiping
    CURRENT OPINION IN IMMUNOLOGY, 2013, 25 (02) : 214 - 221
12345